MRD Evaluation of aumolertinib in EGFR mutation-positive stage IB and stage IA2-3 NSCLC after complete surgical resection: A multicenter, open-label, single-arm study (ASSIST)

被引：0
|
作者：
Cheng, C. [1 ]
Li, H. [2 ]
Zhang, J. [3 ]
Ben, X. [4 ]
Li, S. [5 ]
Wang, D. [6 ]
Lin, W. [7 ]
Lv, W. [8 ]
机构：
[1] Sun Yat Sen Univ, Affiliated Hosp 1, Thorac Surg, Guangzhou, Peoples R China
[2] Southern Med Univ, Zhujiang Hosp, Thorac Surg, Guangzhou, Peoples R China
[3] Sun Yat Sen Univ, Affiliated Hosp 3, Cardiothorac Surg, Guangzhou, Peoples R China
[4] Guangdong Prov Peoples Hosp, Thorac Surg, Guangzhou, Peoples R China
[5] Guangzhou Med Univ, Affiliated Hosp 1, Thorac Surg, Guangzhou, Peoples R China
[6] Shanwei Yiwei Fund Hosp, Radiol, Shanwei, Peoples R China
[7] Gaozhou Peoples Hosp, Thorac Surg, Gaozhou, Peoples R China
[8] Jieyang Peoples Hosp, Cardiothorac Surg, Jieyang, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
104TiP
引用
收藏
页码：S100 / S100
页数：1
相关论文
共 30 条
  • [1] First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study
    Douillard, J-Y
    Ostoros, G.
    Cobo, M.
    Ciuleanu, T.
    McCormack, R.
    Webster, A.
    Milenkova, T.
    BRITISH JOURNAL OF CANCER, 2014, 110 (01) : 55 - 62
  • [2] First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study
    J-Y Douillard
    G Ostoros
    M Cobo
    T Ciuleanu
    R McCormack
    A Webster
    T Milenkova
    British Journal of Cancer, 2014, 110 : 55 - 62
  • [3] Osimertinib as adjuvant therapy in patients with stage IB-IIIA EGFR mutation-positive (EGFRm) NSCLC after complete tumour resection: ADAURA
    John, Thomas
    Herbst, Roy
    Tsuboi, Masahiro
    Grohe, Christian
    Majem, Margarita
    Goldman, Jonathan W.
    Kim, Sang-We
    Marmol, Dominika
    Rukazenkov, Yuri
    Wu, Yi-Long
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 : 69 - 70
  • [4] Adjuvant Osimertinib in Patients With Stage IB to IIIA EGFR Mutation-Positive NSCLC After Complete Tumor Resection: ADAURA China Subgroup Analysis
    Wang, Jie
    Wu, Yi-Long
    Lu, Shun
    Wang, Qun
    Li, Shanqing
    Zhong, Wen-Zhao
    Wang, Qiming
    Li, Wei
    Wang, Buhai
    Chen, Jun
    Cheng, Ying
    Duan, Hongbing
    Li, Gaofeng
    Shan, Li
    Liu, Yangbo
    Liu, Jing
    Huang, Xiangning
    Bolanos, Ana
    He, Jie
    JTO CLINICAL AND RESEARCH REPORTS, 2024, 5 (02):
  • [5] TARGET: A Phase II, Open-Label, Single-Arm Study of 5-Year Adjuvant Osimertinib in Completely Resected EGFR-Mutated Stage II to IIIB NSCLC Post Complete Surgical Resection
    Soo, Ross Andrew
    de Marinis, Filippo
    Han, Ji-Youn
    Ho, James Chung-Man
    Martin, Emma
    Servidio, Leslie
    Sandelin, Martin
    Popat, Sanjay
    CLINICAL LUNG CANCER, 2024, 25 (01) : 80 - 84
  • [6] Neoadjuvant gefitinib for stage II-IIIA NSCLC with activating EGFR mutation (NCT01833572): an open-label, single-arm, phase II study.
    Gongt, Ranxia
    Hu, Haichuan
    Chen, Haiquan
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [7] Adjuvant osimertinib in patients (pts) with stage IB-IIIA EGFR mutation-positive (EGFRm) NSCLC after complete tumour resection: ADAURA China subgroup analysis
    Jie, W.
    Wu, Y-L.
    Lu, S.
    Wang, Q.
    Li, S.
    Zhong, W.
    Wang, Q.
    Li, W.
    Wang, B.
    Chen, J.
    Cheng, Y.
    Duan, H.
    Li, G.
    Shan, L.
    Liu, Y.
    Huang, X.
    Atasoy, A.
    He, J.
    ANNALS OF ONCOLOGY, 2022, 33 : S73 - S73
  • [8] ADAURA: Phase III, Double-blind, Randomized Study of Osimertinib Versus Placebo in EGFR Mutation-positive Early-stage NSCLC After Complete Surgical Resection
    Wu, Yi-Long
    Herbst, Roy S.
    Mann, Helen
    Rukazenkov, Yuri
    Marotti, Marcelo
    Tsuboi, Masahiro
    CLINICAL LUNG CANCER, 2018, 19 (04) : E533 - E536
  • [9] Gefitinib Maintenance After Definitive CCRT in EGFR mutant Stage III NSCLC: Single Arm, Open Label, Multicenter Phase 2 Trial
    Jang, Y.
    Choi, C. -M.
    Oh, I. -J.
    Kim, Y. -C.
    Ji, W.
    Lee, J. C.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S334 - S335
  • [10] Ficonalkib (SY-3505) in Advanced ALK-Positive NSCLC: A Multicenter, Open-Label, Single-Arm, Phase 1/2 Study
    Shi, Yuankai
    Hu, Xingsheng
    Li, Xingya
    Gong, Caifeng
    Wang, Ke
    Li, Yongsheng
    Zhang, Shucai
    Luo, Yongzhong
    Wang, Pingli
    Jiang, Liyan
    Meng, Xiangjiao
    Dong, Xiaorong
    Wang, Huijuan
    Yang, Runxiang
    Mei, Qi
    Liu, Baogang
    Yang, Limin
    Sun, Yinghui
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (06) : 898 - 911
123